Clinical Trial Update: Molecular Disease Characterization Initiative (MDCI) [Phase 2]

View source ↗

Summary

Phase 2 trial update for the Molecular Disease Characterization Initiative (MDCI) in non-small cell lung cancer; the study is terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell, Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2024-04-19